1D8N18 was therefore used as the basis for a bispecific tumor-targeted trimerbody, 1D8N/CEGa1, by adding the epidermal growth factor receptor (EGFR)-binding EGa1 single-domain antibody32. The gene discussed is EGFR; the disease is neoplasm.